米托蒽醌联合用药治疗成人急性白血病临床观察

OBSERVATION OF CLINICAL CURATIVE EFFECT FOR ACUTE LEUKEMIA USING MITOXANTRONE AND OTHER CHEMOTHERAPY AGENTS

目的 :观察米托蒽醌 ( MTZ)治疗初治、复发急性白血病 ( AL)的临床疗效和毒副作用。探索以 MTZ为主要药物作为一线治疗药物的可行性。方法 :急性髓细胞白血病 ( AML)诱导治疗采用 MTZ和阿糖胞苷 ( Ara-C)。急性淋巴细胞白血病 ( AL L)诱导治疗采用长春新碱 ( VCR)、MTZ、异环磷酰胺 ( IFO)和强的松 ( Pred) ,条件允许时加用左旋门冬酰胺酶 ( L-ASP)。结果 :37例患者中 2 9例取得完全缓解 ( CR) ,CR率 78.4%。对 2 0例 AML患者进行了随访 ,治疗多于 6疗程以上的 10例患者 ,有 8例持续 CR( CCR) ,中位缓解期 15 .5月。结论 :米托蒽醌联合用药治疗急性白血病有较好的疗效 ,其毒副作用可以耐受。该方案可以作为一线方案用于

Objective:Observation of clinical curative effect and side effect for newly diagnosed and recurrent acute leukemia (AL) using mitoxantrone (MTZ) and other chemotherapy agents.To explore feasibility of combination mitoxantrone and other agents as first line treatment.Methods:Induction regiment of acute myeloid leukemia (AML) consisted of mitoxantrone and cytosine arabinoside (Ara C).Induction regiment of acute lymphoblastic leukemia (ALL) included at least vincristine (VCR),MTZ,IFO and predisone,it is necessary to use L ASP.Results:39 patients entered the study,29 patients achieve complete remission (CR78.4%).Follow up 20 AML patients,10 patients of more than 6 courses of treatment have 8 patients continous complete remission (CCR).Median remission stage is 15.5 months.Conclusion:Combination mitoxantrone and other agents was found to have sufficient curative effect.The regimens may be regard as first line regimens of treatment to induction treatment of acute leukemia.